Drugs / anivamersen
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01872572 | Aug → Dec 2009 | — | Regado Biosciences, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00932100 | Jul 2009 → Jan 2011 | acute coronary syndrome | Regado Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00715455 | Oct 2007 → Oct 2008 | coronary artery disorder | Regado Biosciences, Inc. | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01848106 | Sep 2013 → Aug 2014 | coronary artery disorder | Regado Biosciences, Inc. | Terminated | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anivamersen | “The REG2 anticoagulation system consists of pegnivacogin, a subcutaneously administered aptamer factor IXa inhibitor, and its intravenous control agent, anivamersen.” PMID 22500821 ↗ Jul 20122“the REG1 system consisting of pegnivacogin, an aptameric factor IXa inhibitor, and its controlling agent anivamersen” PMID 24929350 ↗ Aug 2014 |
| Known as | RB007 | “REG1, an anticoagulation system, consists of RB006 (pegnivacogin), an RNA oligonucleotide factor IXa inhibitor, and RB007 (anivamersen), its complementary controlling agent.” PMID 21315207 ↗ Feb 20111“The antidote component, RB007, is a complementary nucleic acid that binds to and neutralizes RB006.” NCT00715455 ↗ |
| Modality | Oligonucleotide (other) | “The antidote component, RB007, is a complementary nucleic acid that binds to and neutralizes RB006.” NCT00715455 ↗ |
| Route | Intravenous | “The antidote (RB007) is administered as an IV bolus dose” NCT00715455 ↗ |